ELSEVIER

European Journal of Pharmacology
Molecular Pharmacology Section 290 (1995) 267–269

ejp
molecular pharmacology

# Author index

Abdel Ghani, E.M., see Storch, A. (290) 207
Åkerman, K.E.O., see Jansson, C.C. (290) 75
Albuquerque, E.X., see Storch, A. (290) 207
Aoyagi, T., see Sata, M. (290) 55
Aragonés, M.D., see Catalán, R.E. (290) 183
Arneric, S.P., see Gopalakrishnan, M. (290) 237

Barbier, P., Renzetti, A.R., Turbanti, L., Di Bugno, C., Fornai, F., Vaglini, F., Maggio, R. and Corsini, G.U.
Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine (290) 125
Barnes, P.J., see Haddad, E.-B. (290) 201
Bazan, E., Campbell, A.K. and Rapoport, R.M.
Time course of phorbol ester-induced contraction and protein kinase C activation in rat aorta (290) 253
Bertrand, D., see Gopalakrishnan, M. (290) 237
Bianchi, N., see Feriotto, G. (290) 85
Bouvier, C., Bunzow, J.R., Guan, H.-C., Unteutsch, A., Civelli, O., Grandy, D.K. and Van Tol, H.H.M.
Functional characterization of the human dopamine $D_{4.2}$ receptor using vaccinia virus as an expression system (290) 11
Broad, L.M., see Murphy, T.V. (290) 145
Buisson, B., see Gopalakrishnan, M. (290) 237
Bunn, S.J. and Saunders, H.I.
Staurosporine inhibits inositol phosphate formation in bovine adrenal medullary cells (290) 227
Bunzow, J.R., see Bouvier, C. (290) 11
Burnette, E., see Xiong, Z. (290) 117

Campbell, A.D., Womer, D.E. and Simon, J.R.
The 5-$HT_3$ receptor agonist 1-(*m*-chlorophenyl)-biguanide interacts with the dopamine transporter in rat brain synaptosomes (290) 157
Campbell, A.K., see Bazan, E. (290) 253
Campbell, J.E., see Gopalakrishnan, M. (290) 237
Cancedda, E., see Giorgi, O. (290) 37
Catalán, R.E., Martínez, A.M., Aragonés, M.D., Lombardía, M. and Garde, E.
PCA-4248, a PAF receptor antagonist, inhibits PAF-induced phosphoinositide turnover (290) 183
Cebers, G. and Liljequist, S.
Modulation of AMPA/kainate receptors by cyclothiazide increases cytoplasmic free $Ca^{2+}$ and $^{45}Ca^{2+}$ uptake in brain neurons (290) 105
Cheung, D.W., see Xiong, Z. (290) 117
Chio, C.L., see Mierau, J. (290) 29
Christopoulos, A. and Mitchelson, F.
[$^3$H]*N*-Methylscopolamine dissociation from muscarine receptors affected by low concentrations of allosteric modulators (290) 259
Civelli, O., see Bouvier, C. (290) 11
Cooper, J.C., see Storch, A. (290) 207
Corda, M.G., see Giorgi, O. (290) 37
Corsini, G.U., see Barbier, P. (290) 125
Criscuoli, M., see Renzetti, A.R. (290) 151

Danhof, M., see Van der Wenden, E.M. (290) 189
Das, S., see Luo, D. (290) 247
Di Bugno, C., see Barbier, P. (290) 125
DiSanto, M.E. and Heaslip, R.J.
Rolipram inhibition of phosphodiesterase-4 activation (290) 169
Donnelly-Roberts, D., see Gopalakrishnan, M. (290) 237

Elzinga, C.R.S., see Hoiting, B.H. (290) R5
Ensinger, H.A., see Mierau, J. (290) 29

Feriotto, G., Mischiati, C., Bianchi, N., Passadore, M. and Gambari, R.
Binding of distamycin and chromomycin to human immunodeficiency type 1 virus DNA: a non-radioactive automated footprinting study (290) 85
Fornai, F., see Barbier, P. (290) 125
Foster, A.C., see Grimwood, S. (290) 221
Friedman, E., see Tilakaratne, N. (290) 263
Fulcrand, P., see Lallement, J.-C. (290) 61

Galleyrand, J.-C., see Lallement, J.-C. (290) 61
Gambari, R., see Feriotto, G. (290) 85
Garde, E., see Catalán, R.E. (290) 183
Garland, C.J., see Murphy, T.V. (290) 141
Garland, C.J., see Murphy, T.V. (290) 145
Giordano, T., see Gopalakrishnan, M. (290) 237
Giorgi, O., Lecca, D., Cancedda, E., Serra, G.P. and Corda, M.G.
Modulation of [$^{35}$S]TBPS binding by ligands with preferential affinity for benzodiazepine $BZ_1$ sites in the cerebral cortex of newborn and adult rats (290) 37
Gopalakrishnan, M., Buisson, B., Touma, E., Giordano, T., Campbell, J.E., Hu, I.C., Donnelly-Roberts, D., Arneric, S.P., Bertrand, D. and Sullivan, J.P.
Stable expression and pharmacological properties of the human $\alpha_7$ nicotinic acetylcholine receptor (290) 237
Graham, D., see Pimoule, C. (290) 49
Grandy, D.K., see Bouvier, C. (290) 11
Grimwood, S., Kulagowski, J.J., Mawer, I.M., Rowley, M., Leeson, P.D. and Foster, A.C.
Allosteric modulation of the glutamate site on the NMDA receptor by four novel glycine site antagonists (290) 221
Guan, H.-C., see Bouvier, C. (290) 11
Gutbrod, O., see Storch, A. (290) 207

Haddad, E.-B., Rousell, J. and Barnes, P.J.
Muscarinic $M_2$ receptor synthesis: study of receptor turnover with propylbenzilylcholine mustard (290) 201
Hartog-Witte, H.R., see Van der Wenden, E.M. (290) 189
Heaslip, R.J., see DiSanto, M.E. (290) 169
Helmeste, D.M., Tang, S.W., Reist, C. and Vu, R.
Erratum to: 'Serotonin uptake inhibitors modulate intracellular $Ca^{2+}$ mobilization in platelets'. Eur. J. Pharmacol. -- Mol. Pharmacol. Sect. 288 (1995) 373--477 (290) 173

Hermsen, B., see Storch, A. (290) 207
Hoiting, B.H., Kuipers, R., Elzinga, C.R.S., Zaagsma, J. and Meurs, H.
Feedforward control of agonist-induced $Ca^{2+}$ signalling by protein kinase C in airway smooth muscle cells (290) R5
Hu, I.C., see Gopalakrishnan, M. (290) 237
Huff, R.M., see Mierau, J. (290) 29

IJzerman, A.P., see Van der Wenden, E.M. (290) 189
Ikeda, U., Kanbe, T., Nakayama, I., Kawahara, Y., Yokoyama, M. and Shimada, K.
Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1$\beta$ (290) 69

Jansson, C.C., Karp, M., Oker-Blom, C., Näsman, J., Savola, J.-M. and Åkerman, K.E.O.
Two human $\alpha_2$-adrenoceptor subtypes $\alpha_2$A-C10 and $\alpha_2$B-C2 expressed in *Sf9* cells couple to transduction pathway resulting in opposite effects on cAMP production (290) 75
Johansen, P.A. and Robinson, M.B.
Identification of 2-amino-2-methyl-4-phosphonobutanoic acid as an antagonist at the $mGlu_{4a}$ receptor (290) R1

Kanbe, T., see Ikeda, U. (290) 69
Karp, M., see Jansson, C.C. (290) 75
Kawahara, Y., see Ikeda, U. (290) 69
Kessler, T. and Lugnier, C.
Rolipram increases cyclic GMP content in L-arginine-treated cultured bovine aortic endothelial cells (290) 163
Kokubu, N., Satoh, M. and Takayanagi, I.
Involvement of botulinum $C_3$-sensitive GTP-binding proteins in $\alpha_1$-adrenoceptor subtypes mediating $Ca^{2+}$-sensitization (290) 19
Kuipers, R., see Hoiting, B.H. (290) R5
Kulagowski, J.J., see Grimwood, S. (290) 221

Lajiness, M.E., see Mierau, J. (290) 29
Lallement, J.-C., Oiry, C., Lima-Leite, A.-C., Lignon, M.-F., Fulcrand, P., Galleyrand, J.-C. and Martinez, J.
Cholecystokinin and gastrin are not equally sensitive to GTP$\gamma$S at $CCK_B$ receptors: importance of the sulphated tyrosine (290) 61
Langer, S.Z., see Pimoule, C. (290) 49
Lecca, D., see Giorgi, O. (290) 37
Leclerc, L., see Zaidi, A. (290) 133
Leeson, P.D., see Grimwood, S. (290) 221
Lemmer, B., see Witte, K. (290) 1
Lidaks, M.J., see Van der Wenden, E.M. (290) 189
Lignon, M.-F., see Lallement, J.-C. (290) 61
Liljequist, S., see Cebers, G. (290) 105
Lima-Leite, A.-C., see Lallement, J.-C. (290) 61
Lobron, C., see Storch, A. (290) 207
Lombardía, M., see Catalán, R.E. (290) 183
Lugnier, C., see Kessler, T. (290) 163
Luo, D., Das, S. and Vincent, S.R.
Effects of methylene blue and LY83583 on neuronal nitric oxide synthase and NADPH-diaphorase (290) 247

Maelicke, A., see Storch, A. (290) 207
Maggio, R., see Barbier, P. (290) 125
Marden, M.C., see Zaidi, A. (290) 133
Martínez, A.M., see Catalán, R.E. (290) 183
Martinez, J., see Lallement, J.-C. (290) 61
Mathôt, R.A.A., see Van der Wenden, E.M. (290) 189
Mawer, I.M., see Grimwood, S. (290) 221
McKernan, R.M., see Quirk, K. (290) 175
Methfessel, C., see Storch, A. (290) 207
Meurs, H., see Hoiting, B.H. (290) R5
Mierau, J., Schneider, F.J., Ensinger, H.A., Chio, C.L., Lajiness, M.E. and Huff, R.M.
Pramipexole binding and activation of cloned and expressed dopamine $D_2$, $D_3$ and $D_4$ receptors (290) 29
Mischiati, C., see Feriotto, G. (290) 85
Mitchelson, F., see Christopoulos, A. (290) 259
Momomura, S.-i., see Sata, M. (290) 55
Murphy, T.V. and Garland, C.J.
Specific accumulation of inositol 1,4,5-trisphosphate in rabbit basilar artery in response to noradrenaline but not 5-hydroxytryptamine (290) 141
Murphy, T.V., Broad, L.M. and Garland, C.J.
Characterisation of inositol 1,4,5-trisphosphate binding sites in rabbit aortic smooth muscle (290) 145

Nakayama, I., see Ikeda, U. (290) 69
Näsman, J., see Jansson, C.C. (290) 75

Oiry, C., see Lallement, J.-C. (290) 61
Oker-Blom, C., see Jansson, C.C. (290) 75
Olbrich, H.-G., see Witte, K. (290) 1

Palmier, C., see Pauwels, P.J. (290) 95
Passadore, M., see Feriotto, G. (290) 85
Pauwels, P.J. and Palmier, C.
Functional effects of the 5-$HT_{1D}$ receptor antagonist GR 127,935 at human 5-$HT_{1D\alpha}$, 5-$HT_{1D\beta}$, 5-$HT_{1A}$ and opossum 5-$HT_{1B}$ receptors (290) 95
Pereira, E.F.R., see Storch, A. (290) 207
Pimoule, C., Langer, S.Z. and Graham, D.
Further evidence that the classical $\alpha_{1A}$- and cloned $\alpha_{1c}$-adrenoceptors are the same subtype (290) 49
Pirovano, I.M., see Van der Wenden, E.M. (290) 189
Poyart, C., see Zaidi, A. (290) 133

Quirk, K., Whiting, P.J., Ragan, C.I. and McKernan, R.M.
Characterisation of $\delta$-subunit containing $GABA_A$ receptors from rat brain (290) 175

Ragan, C.I., see Quirk, K. (290) 175
Rapoport, R.M., see Bazan, E. (290) 253
Reinhardt, S., see Storch, A. (290) 207
Reist, C., see Helmeste, D.M. (290) 173
Renzetti, A.R., Criscuoli, M., Salimbeni, A. and Subissi, A.
Molecular pharmacology of LR-B/081, a new non-peptide angiotensin $AT_1$ receptor antagonist (290) 151
Renzetti, A.R., see Barbier, P. (290) 125
Robinson, M.B., see Johansen, P.A. (290) R1
Roelen, H.C.P.F., see Van der Wenden, E.M. (290) 189
Rousell, J., see Haddad, E.-B. (290) 201
Rowley, M., see Grimwood, S. (290) 221

Salimbeni, A., see Renzetti, A.R. (290) 151
Sata, M., Sugiura, S., Yamashita, H., Aoyagi, T., Momomura, S.-i. and Serizawa, T.
Pimobendan directly sensitizes reconstituted thin filament to slide on cardiac myosin (290) 55
Satoh, M., see Kokubu, N. (290) 19
Saunders, H.I., see Bunn, S.J. (290) 227
Savola, J.-M., see Jansson, C.C. (290) 75
Schnecko, A., see Witte, K. (290) 1
Schneider, F.J., see Mierau, J. (290) 29
Schrattenholz, A., see Storch, A. (290) 207
Serizawa, T., see Sata, M. (290) 55
Serra, G.P., see Giorgi, O. (290) 37
Shimada, K., see Ikeda, U. (290) 69
Simon, J.R., see Campbell, A.D. (290) 157
Šoškiç, V., see Storch, A. (290) 207
Soudijn, W., see Van der Wenden, E.M. (290) 189

Storch, A., Schrattenholz, A., Cooper, J.C., Abdel Ghani, E.M., Gutbrod, O., Weber, K.-H., Reinhardt, S., Lobron, C., Hermsen, B., Šoškiç, V., Pereira, E.F.R., Albuquerque, E.X., Methfessel, C. and Maelicke, A. Physostigmine, galanthamine and codeine act as 'noncompetitive nicotinic receptor agonists' on clonal rat pheochromocytoma cells (290) 207
Subissi, A., see Renzetti, A.R. (290) 151
Sugiura, S., see Sata, M. (290) 55
Sullivan, J.P., see Gopalakrishnan, M. (290) 237

Takayanagi, I., see Kokubu, N. (290) 19
Tang, S.W., see Helmeste, D.M. (290) 173
Tilakaratne, N., Yang, Z. and Friedman, E. Chronic fluoxetine or desmethylimipramine treatment alters 5-$HT_2$ receptor mediated c-*fos* gene expression (290) 263
Touma, E., see Gopalakrishnan, M. (290) 237
Turbanti, L., see Barbier, P. (290) 125

Unteutsch, A., see Bouvier, C. (290) 11

Vaglini, F., see Barbier, P. (290) 125
Van Aerschot, A., see Van der Wenden, E.M. (290) 189
Van der Wenden, E.M., Hartog-Witte, H.R., Roelen, H.C.P.F., Von Frijtag Drabbe Künzel, J.K., Pirovano, I.M., Mathôt, R.A.A., Danhof, M., Van Aerschot, A., Lidaks, M.J., IJzerman, A.P. and Soudijn, W. 8-Substituted adenosine and theophylline-7-riboside analogues as potential partial agonists for the adenosine $A_1$ receptor (290) 189
Van Tol, H.H.M., see Bouvier, C. (290) 11
Vincent, S.R., see Luo, D. (290) 247
Von Frijtag Drabbe Künzel, J.K., see Van der Wenden, E.M. (290) 189
Vu, R., see Helmeste, D.M. (290) 173

Weber, K.-H., see Storch, A. (290) 207
Whiting, P.J., see Quirk, K. (290) 175
Witte, K., Schnecko, A., Olbrich, H.-G. and Lemmer, B. Efficiency of $\beta$-adrenoceptor subtype coupling to cardiac adenylyl cyclase in cardiomyopathic and control hamsters (290) 1
Womer, D.E., see Campbell, A.D. (290) 157

Xiong, Z., Burnette, E. and Cheung, D.W. Modulation of $Ca^{2+}$-activated $K^+$ channel activity by tyrosine kinase inhibitors in vascular smooth muscle cell (290) 117

Yamashita, H., see Sata, M. (290) 55
Yang, Z., see Tilakaratne, N. (290) 263
Yokoyama, M., see Ikeda, U. (290) 69

Zaagsma, J., see Hoiting, B.H. (290) R5
Zaidi, A., Marden, M.C., Poyart, C. and Leclerc, L. Protection by lazaroids of the erythrocyte ($Ca^{2+}$, $Mg^{2+}$)-ATPase against iron-induced inhibition (290) 133